{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:08:24Z","timestamp":1778724504124,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016040","name":"S. H. Ho Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.010","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:02:35Z","timestamp":1773889355000},"page":"273-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytoreductive Radical Prostatectomy in Men with De Novo Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Radhika","family":"Ragam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monish","family":"Aron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2026.02.010_bib1","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.ucl.2026.02.010_bib4","article-title":"SEER explorer application. An interactive website for SEER cancer statistics","year":"2023","journal-title":"Surveillance Research Program"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.010_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4274\/uob.galenos.2022.2022.10.6","article-title":"Obstructive uropathy in advanced prostate cancer","volume":"22","author":"Erbatu","year":"2023","journal-title":"Bulletin of Urooncology"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.010_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/tre.916","article-title":"New developments in the management of newly diagnosed metastatic prostate cancer","volume":"14","author":"Leone","year":"2023","journal-title":"Trends in Urology & Men\u2019s Health"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.010_bib7","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0022-5347(17)54306-2","article-title":"Treatment of a metastatic prostate derived tumor with surgery and chemotherapy","volume":"127","author":"Kadmon","year":"1982","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.010_bib8","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3892\/ol.2015.3522","article-title":"Development of an orthotopic model of human metastatic prostate cancer in the NOD-SCID\u03b3 mouse (Mus musculus) anterior prostate","volume":"10","author":"Cifuentes","year":"2015","journal-title":"Oncol Lett"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.010_bib9","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3892\/or.2015.4319","article-title":"Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer","volume":"34","author":"Cifuentes","year":"2015","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.010_bib10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","article-title":"Pre-metastatic niche: formation, characteristics and therapeutic implication","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.010_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10555-013-9481-1","article-title":"Src signaling pathways in prostate cancer","volume":"33","author":"Varkaris","year":"2014","journal-title":"Cancer Metastasis Rev"},{"issue":"18","key":"10.1016\/j.ucl.2026.02.010_bib12","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2010.33.2999","article-title":"Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment","volume":"29","author":"Tzelepi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.010_bib13","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0022-5347(05)64562-4","article-title":"Impact of previous local treatment for prostate cancer on subsequent metastatic disease","volume":"168","author":"Thompson","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.010_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urolonc.2010.02.010","article-title":"Tumor cytoreduction results in better response to androgen ablation\u2014a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer","volume":"30","author":"Qin","year":"2012","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.010_bib15","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1111\/bju.12169","article-title":"Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer","volume":"112","author":"Won","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2026.02.010_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2021.05.006","article-title":"The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. Results from the local treatment of metastatic prostate cancer (LoMP) registry","volume":"29","author":"Lumen","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.010_bib17","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000181826.65272.7b","article-title":"Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer","volume":"174","author":"Leibovici","year":"2005","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.010_bib18","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.010_bib19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.juro.2015.02.084","article-title":"Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis","volume":"194","author":"Satkunasivam","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.010_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.canep.2014.04.002","article-title":"Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis","volume":"38","author":"Antwi","year":"2014","journal-title":"Cancer Epidemiology"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.010_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2014.08.056","article-title":"Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study","volume":"67","author":"Fossati","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.010_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2017.03.020","article-title":"Local therapy improves survival in metastatic prostate cancer","volume":"72","author":"Leyh-Bannurah","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.010_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2016.04.031","article-title":"The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis","volume":"72","author":"L\u00f6ppenberg","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.010_bib24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pros.23294","article-title":"Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer","volume":"77","author":"Parikh","year":"2017","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.010_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.euo.2023.09.006","article-title":"Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a multicenter European Study","volume":"7","author":"Rajwa","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.010_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.prnil.2018.10.002","article-title":"Results of phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer","volume":"7","author":"Yuh","year":"2019","journal-title":"Prostate Int"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.010_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.prnil.2022.03.001","article-title":"Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy","volume":"10","author":"Kim","year":"2022","journal-title":"Prostate Int"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.010_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bju.15553","article-title":"Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study)","volume":"129","author":"Buelens","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2026.02.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.09.4144","article-title":"Best systemic therapy with or without radical prostatectomy in the management of men with oligometastatic prostate cancer: the RAMPP randomized controlled trial","author":"Graefen","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.010_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bju.15669","article-title":"Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial","volume":"130","author":"Sooriakumaran","year":"2022","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.010_bib31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.010_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.48057","article-title":"Local treatment and treatment-related adverse effects among patients with advanced prostate cancer","volume":"6","author":"Khan","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.010_bib35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","article-title":"Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study","volume":"193","author":"Heidenreich","year":"2015","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.010_bib36","doi-asserted-by":"crossref","first-page":"e939","DOI":"10.1016\/j.clgc.2019.05.022","article-title":"Comparison of open versus robotically assisted cytoreductive radical prostatectomy for metastatic prostate cancer","volume":"17","author":"Preisser","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.010_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12894-024-01463-2","article-title":"Minimally invasive cytoreductive radical prostatectomy, exploring the safety and feasibility of a single-port or multi-port robotic platform","volume":"24","author":"Lama","year":"2024","journal-title":"BMC Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.010_bib38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bju.16370","article-title":"Peri-operative outcomes following radical prostatectomy in the setting of advanced prostate cancer","volume":"134","author":"Simhal","year":"2024","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.010_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/1008-682X.196852","article-title":"Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study","volume":"20","author":"Kim","year":"2018","journal-title":"Asian J Androl"},{"key":"10.1016\/j.ucl.2026.02.010_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2017.02.051","article-title":"Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective local treatment of metastatic prostate cancer (LoMP) trial","volume":"106","author":"Poelaert","year":"2017","journal-title":"Urology"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:21:31Z","timestamp":1778721691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000108"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.010","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytoreductive Radical Prostatectomy in Men with De Novo Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}